Author:
Lin Hui,Jiang Hong,Chen Qiang,Pan Xiang,Deng Mei,Cai Xiang-Ran,Lu Yuan-Zhi,Song Yuan-Zong,Liu Jun-Cheng
Abstract
AbstractDeficiency of citrin, the liver-type aspartate-glutamate carrier, arises from biallelic mutations of the gene SLC25A13. Although citrin deficiency (CD) is associated with higher risk of hepatocellular carcinoma (HCC) in adult patients, this association remains inconclusive in pediatric cases. The patient in this paper had been diagnosed to have CD by SLC25A13 analysis at the age 10 months, and then in response to dietary therapy, her prolonged jaundice and marked hepatosplenomegaly resolved gradually. However, she was referred to the hospital once again due to recurrent abdominal distention for 2 weeks at her age 4 years and 9 months, when prominently enlarged liver and spleen were palpated, along with a strikingly elevated serum alpha-fetoprotein (AFP) level of 27605 ng/mL as well as a large mass in the right liver lobe and a suspected tumor thrombus within the portal vein on enhanced computed tomography. After 4 rounds of adjuvant chemotherapy, right hepatic lobectomy and portal venous embolectomy were performed at her age 5 years and 3 months, and metastatic hepatoblastoma was confirmed by histopathological analysis. Afterwards, the patient underwent 5 additional cycles of chemotherapy and her condition remained stable for 7 months after surgery. Unfortunately, hepatoblastoma recurred in the left lobe at the age 5 years and 10 months, which progressed rapidly into liver failure, and led to death at the age 6 years and 1 month. As far as we know, this is the the first case of hepatoblastoma in a patient with CD, raising the possibility of an association between these two conditions.
Funder
National Natural Science Foundation of China
Science and Technology Plan Project of Guangzhou City
Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Tavoulari S, Lacabanne D, Thangaratnarajah C, Kunji ERS. Pathogenic variants of the mitochondrial aspartate/glutamate carrier causing citrin deficiency. Trends Endocrinol Metab. 2022;33(8):539–53. https://doi.org/10.1016/j.tem.2022.05.002.
2. Kobayashi K, Sinasac DS, Iijima M, Boright AP, Begum L, Lee JR, et al. The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat Genet. 1999;22(2):159–63. https://doi.org/10.1038/9667.
3. Zhang T, Zhu S, Miao H, Yang J, Shi Y, Yue Y, et al. Dynamic changes of metabolic characteristics in neonatal intrahepatic cholestasis caused by citrin deficiency. Front Mol Biosci. 2022;9:939837. https://doi.org/10.3389/fmolb.2022.939837.
4. Song YZ, Deng M, Chen FP, Wen F, Guo L, Cao SL, et al. Genotypic and phenotypic features of citrin deficiency: five-year experience in a Chinese pediatric center. Int J Mol Med. 2011;28(1):33–40. https://doi.org/10.3892/ijmm.2011.653.
5. Saheki T, Song YZ. Citrin deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews®. Seattle: University of Washington; 2005.